Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 4/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 9/20 | 0.36 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25241849 | 0.87 | P2RX3 (0.42) | PTGDR2PDK2 | |
| SCHEMBL20818287 | 0.82 | PTGDR2 (0.40) | PTGDR2PDK2P2RX7 | |
| SCHEMBL20818699 | 0.81 | PTGDR2 (0.41) | PTGDR2PDK2P2RX7 | |
| SCHEMBL20818039 | 0.81 | PTGDR2 (0.42) | PTGDR2PDK2P2RX7 | |
| SCHEMBL25285486 | 0.80 | TRPC5 (0.52) | PTGDR2PDK2P2RX7TRPC5 | |
| SCHEMBL20817901 | 0.80 | PTGDR2 (0.41) | PTGDR2PDK2P2RX7TRPC5 | |
| SCHEMBL20818239 | 0.78 | TRPC5 (0.33) | TRPC5 | |
| SCHEMBL25281968 | 0.77 | KDM4E (0.42) | — | |
| SCHEMBL20818472 | 0.77 | PTGDR2 (0.39) | PTGDR2PDK2P2RX7 | |
| SCHEMBL20818154 | 0.76 | TRPC5 (0.50) | TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2023-06-29 | — | — | US | disclosed |
| EP-3684364-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019055966-A2 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203028-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | PDXK, ATP6V1B1, REN | PTGDR2 584/4885PDK2 17/4885P2RX7 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.